FIELD: medicine.
SUBSTANCE: system is distinguished by reduced formation of oxidation decomposition products during transdermal therapeutic system storage time that is related to at least one active substance containing in given system capable of being oxidized with hyperoxides. The transdermal therapeutic system is characterized in that peroxidation number (POZ) sum of auxiliary substances in the drug containing one or several active substances relative to proportion selected according to transdermal therapeutic system formulation is not greater than 20.
EFFECT: reduced quantity of oxidation products.
11 cl
| Title | Year | Author | Number |
|---|---|---|---|
| FILM-TYPE PREPARATIONS OF HIGH CHEMICAL STABILITY, CONTAINING ACTIVE INGREDIENT, AND METHOD FOR PRODUCING THEM | 2003 |
|
RU2311900C2 |
| ESTRADIOL-CONTAINING TRANSDERMAL THERAPEUTIC SYSTEM | 1994 |
|
RU2140784C1 |
| TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE | 2019 |
|
RU2798017C2 |
| TRANSDERMAL PLASTER | 2010 |
|
RU2445084C2 |
| TRANSDERMAL THERAPEUTIC SYSTEM AND METHOD FOR PRODUCING THE SYSTEM | 1993 |
|
RU2108812C1 |
| TRANSDERMAL THERAPEUTIC SYSTEM | 1989 |
|
RU2011384C1 |
| HIGHLY PURE 3,3-DIPHENYLPROPYLAMINO MONOESTERS | 2004 |
|
RU2394019C2 |
| TRANSDERMAL THERAPEUTIC SYSTEM USING HEAT AVAILABLE TO ACCELERATE PENETRATION OF BIOLOGICALLY ACTIVE SUBSTANCES, AND APPLICATION THEREOF | 2004 |
|
RU2348397C2 |
| TRANSDERMAL PLASTER | 2010 |
|
RU2445123C2 |
| PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ALPRAZOLAM | 2018 |
|
RU2694232C1 |
